NCT04107077View on ClinicalTrials.gov

Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

September 9, 2025

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2026

Conditions
Gastric CancerPeritoneal Carcinomatosis
Interventions
DRUG

Cisplatin

Laparoscopic HIPEC will be performed at a maximum of two (2) times spaced approximately 6 weeks apart. The dosing of the drugs will be the same during each administration but adjusted if needed based on lab work. The typical dosages are 200mg of Cisplatin

DRUG

Mitomycin

Laparoscopic HIPEC will be performed at a maximum of two (2) times spaced approximately 6 weeks apart. The dosing of the drugs will be the same during each administration but adjusted if needed based on lab work. The typical dosages are 30mg of Mitomycin C.

Trial Locations (1)

60637

RECRUITING

University of Chicago, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER

NCT04107077 - Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer | Biotech Hunter | Biotech Hunter